Bioartificial Intelligence™ ("bioAI") Human Therapeutic Antibodies
About 200 therapeutic antibodies ('tAbs") were approved or under regulatory review in the US and Europe by the end of 2023 (Antibody Society, December 2023), each generated with in vivo platforms such as normal or human Ig transgenic animals, in vitro platforms such as phage display, or cloning from humans.
Artificial Intelligence ("AI") is increasingly being used to create tAbs de novo or via deep learning using "training sets". Established AI models can be used to evaluate tAbs not present during the training stage or generate entirely new tAbs ("Generative AI"). Language models learning word meanings from contexts are also being explored for human tAb discovery, yet with less success so far.
Abvivo's Bioartificial Intelligence™ refers to the use of the clinically and commercially most proven human Ig transgenic animal platforms, including heavy chain-only ("HCO") birds for domain antibodies ('dAbs"), and efficient B cell cloning technologies to first generate selective tAbs against challenging targets, then deploying these as training sets to produce superior development candidates that would be highly unlikely with traditional tAb discovery platforms or AI alone.
Abvivo's Bioartificial Intelligence™ enables its licensees to generate mono-, bi-, and multi-specific tAbs in conventional H2L2 and other formats all the way down to dAbs with their tissue penetration, ease of manufacturing, and other benefits. Furthermore, Abvivo's Bioartificial Intelligence™ predicts and tests multi-specific dAb configurations in ways that would be practically impossible without performance AI.
Abvivo designs, generates, and licenses its tAb development candidates to biopharmaceutical companies globally, typically milestone- or royalty-free. Contact bl@abvivo.com for specific opportunities.